Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 110,600 shares, a decline of 38.1% from the November 30th total of 178,800 shares. Based on an average trading volume of 83,200 shares, the short-interest ratio is presently 1.3 days. Approximately 0.6% of the company’s shares are short sold.

Institutional Trading of Aileron Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. University of Texas Texas AM Investment Management Co. purchased a new stake in Aileron Therapeutics during the second quarter worth approximately $4,925,000. Nantahala Capital Management LLC boosted its position in Aileron Therapeutics by 82.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after purchasing an additional 209,367 shares during the period. Sigma Planning Corp boosted its position in Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after purchasing an additional 86,185 shares during the period. Geode Capital Management LLC increased its holdings in Aileron Therapeutics by 34.8% in the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock valued at $814,000 after purchasing an additional 59,370 shares in the last quarter. Finally, Warberg Asset Management LLC purchased a new position in Aileron Therapeutics in the second quarter valued at about $86,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Aileron Therapeutics Price Performance

Aileron Therapeutics stock opened at $2.23 on Friday. The company has a market cap of $48.32 million, a price-to-earnings ratio of -0.71 and a beta of 2.22. Aileron Therapeutics has a 12 month low of $1.61 and a 12 month high of $7.42. The stock’s 50-day moving average is $2.92 and its 200-day moving average is $2.88.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).